These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Arrillaga-Romany I; Lassman A; McGovern SL; Mueller S; Nabors B; van den Bent M; Vogelbaum MA; Allen JE; Melemed AS; Tarapore RS; Wen PY; Cloughesy T Neuro Oncol; 2024 May; 26(Supplement_2):S173-S181. PubMed ID: 38445964 [TBL] [Abstract][Full Text] [Related]
45. H3 K27M-mutant diffuse midline glioma with osseous metastases: A case report and a literature review. Al Sharie S; Talafha M; Abu Laban D; Al Awabdeh T; Al-Mousa A; Al-Masri N; Al-Hussaini M Clin Neuropathol; 2022; 41(6):263-270. PubMed ID: 35770519 [TBL] [Abstract][Full Text] [Related]
46. Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression. Lopez GY; Oberheim Bush NA; Phillips JJ; Bouffard JP; Moshel YA; Jaeckle K; Kleinschmidt-DeMasters BK; Rosenblum MK; Perry A; Solomon DA Acta Neuropathol; 2017 Dec; 134(6):961-963. PubMed ID: 29063183 [No Abstract] [Full Text] [Related]
47. Diffuse midline glioma with H3 K27M mutation of the spinal cord: A series of 33 cases. Yao J; Wang L; Ge H; Yin H; Piao Y Neuropathology; 2021 Jun; 41(3):183-190. PubMed ID: 33599007 [TBL] [Abstract][Full Text] [Related]
48. Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma. Ocasio JK; Budd KM; Roach JT; Andrews JM; Baker SJ Cancer Metastasis Rev; 2023 Jun; 42(2):367-388. PubMed ID: 37119408 [TBL] [Abstract][Full Text] [Related]
49. A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations. Nakano Y; Yamasaki K; Sakamoto H; Matsusaka Y; Kunihiro N; Fukushima H; Inoue T; Honda-Kitahara M; Hara J; Yoshida A; Ichimura K Brain Tumor Pathol; 2019 Oct; 36(4):162-168. PubMed ID: 31254135 [TBL] [Abstract][Full Text] [Related]
50. H3 G34-mutant high-grade glioma. Lim KY; Won JK; Park CK; Kim SK; Choi SH; Kim T; Yun H; Park SH Brain Tumor Pathol; 2021 Jan; 38(1):4-13. PubMed ID: 32995948 [TBL] [Abstract][Full Text] [Related]
51. Identification of genes functionally involved in the detrimental effects of mutant histone H3.3-K27M in Drosophila melanogaster. Berlandi J; Chaouch A; De Jay N; Tegeder I; Thiel K; Shirinian M; Kleinman CL; Jeibmann A; Lasko P; Jabado N; Hasselblatt M Neuro Oncol; 2019 May; 21(5):628-639. PubMed ID: 30715493 [TBL] [Abstract][Full Text] [Related]
52. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker. Agarwal P; Aiyer HM Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633 [TBL] [Abstract][Full Text] [Related]
53. Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR. Zhang R; Han J; Daniels D; Huang H; Zhang Z J Neurooncol; 2016 Jan; 126(1):27-36. PubMed ID: 26376656 [TBL] [Abstract][Full Text] [Related]
54. An H3F3A K27M-mutation in a sonic hedgehog medulloblastoma. Dottermusch M; Uksul N; Knappe UJ; Erdlenbruch B; Wefers AK Brain Pathol; 2022 May; 32(3):e13024. PubMed ID: 34747078 [TBL] [Abstract][Full Text] [Related]
55. Diffuse midline glioma of the cervical spinal cord with H3 K27M genotype phenotypically mimicking anaplastic ganglioglioma: a case report and review of the literature. Kraus TFJ; Machegger L; Pöppe J; Zellinger B; Dovjak E; Schlicker HU; Schwartz C; Ladisich B; Spendel M; Kral M; Reinhardt A; Winkler PA; Sotlar K Brain Tumor Pathol; 2020 Jul; 37(3):89-94. PubMed ID: 32451719 [TBL] [Abstract][Full Text] [Related]
56. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. Arrillaga-Romany I; Gardner SL; Odia Y; Aguilera D; Allen JE; Batchelor T; Butowski N; Chen C; Cloughesy T; Cluster A; de Groot J; Dixit KS; Graber JJ; Haggiagi AM; Harrison RA; Kheradpour A; Kilburn LB; Kurz SC; Lu G; MacDonald TJ; Mehta M; Melemed AS; Nghiemphu PL; Ramage SC; Shonka N; Sumrall A; Tarapore RS; Taylor L; Umemura Y; Wen PY J Clin Oncol; 2024 May; 42(13):1542-1552. PubMed ID: 38335473 [TBL] [Abstract][Full Text] [Related]
57. H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis. Kleinschmidt-DeMasters BK; Mulcahy Levy JM Clin Neuropathol; 2018; 37 (2018)(2):53-63. PubMed ID: 29393845 [TBL] [Abstract][Full Text] [Related]
58. Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort. Hayashi N; Fukai J; Nakatogawa H; Kawaji H; Yoshioka E; Kodama Y; Nakajo K; Uda T; Naito K; Kijima N; Okita Y; Kagawa N; Takahashi Y; Hashimoto N; Arita H; Takano K; Sakamoto D; Iida T; Arakawa Y; Kawauchi T; Sonoda Y; Mitobe Y; Ishibashi K; Matsuda M; Achiha T; Tomita T; Nonaka M; Hara K; Takebe N; Tsuzuki T; Nakajima Y; Ohue S; Nakajima N; Watanabe A; Inoue A; Umegaki M; Kanematsu D; Katsuma A; Sumida M; Shofuda T; Mano M; Kinoshita M; Mori K; Nakao N; Kanemura Y Acta Neuropathol Commun; 2024 Jul; 12(1):120. PubMed ID: 39061104 [TBL] [Abstract][Full Text] [Related]
59. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. Chai RC; Zhang YW; Liu YQ; Chang YZ; Pang B; Jiang T; Jia WQ; Wang YZ Acta Neuropathol Commun; 2020 Mar; 8(1):40. PubMed ID: 32228694 [TBL] [Abstract][Full Text] [Related]
60. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]